These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 25173348

  • 1. Smoking did not modify the effects of anti-TNF treatment on health-related quality of life among Australian ankylosing spondylitis patients.
    Kydd AS, Chen JS, Makovey J, Chand V, Henderson L, Buchbinder R, Lassere M, March LM.
    Rheumatology (Oxford); 2015 Feb; 54(2):310-7. PubMed ID: 25173348
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 3. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 4. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [Abstract] [Full Text] [Related]

  • 5. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Glintborg B, Højgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, Chrysidis S, Jensen Hansen IM, Holland-Fischer M, Højland Hansen T, Nilsson C, Espesen J, Nordin H, Rasmussen Loft AG, Pelck R, Lorenzen T, Flejsborg Oeftiger S, Unger B, Jaeger F, Mosborg Petersen P, Rasmussen C, Dreyer L.
    Rheumatology (Oxford); 2016 Apr; 55(4):659-68. PubMed ID: 26628579
    [Abstract] [Full Text] [Related]

  • 6. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.
    Arthritis Rheum; 2007 Aug 15; 57(6):1050-7. PubMed ID: 17665483
    [Abstract] [Full Text] [Related]

  • 7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 15; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 8. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy.
    Davis JC, van der Heijde D, Dougados M, Woolley JM.
    Arthritis Rheum; 2005 Aug 15; 53(4):494-501. PubMed ID: 16082640
    [Abstract] [Full Text] [Related]

  • 9. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS, McGuigan LE, McGirr EE.
    Int J Rheum Dis; 2014 Feb 15; 17(2):165-72. PubMed ID: 24576272
    [Abstract] [Full Text] [Related]

  • 10. 'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication.
    Stockdale J, Goodacre L.
    Musculoskeletal Care; 2009 Sep 15; 7(3):162-77. PubMed ID: 19065621
    [Abstract] [Full Text] [Related]

  • 11. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

  • 12. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.
    J Rheumatol; 2008 Apr 02; 35(4):662-7. PubMed ID: 18278836
    [Abstract] [Full Text] [Related]

  • 13. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, GO-RAISE investigators.
    J Rheumatol; 2014 Jun 02; 41(6):1095-103. PubMed ID: 24737912
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC, ATLAS Study Group.
    J Rheumatol; 2008 Jul 02; 35(7):1346-53. PubMed ID: 18484692
    [Abstract] [Full Text] [Related]

  • 15. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 02; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 16. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM, Burgos-Vargas R, Laxer RM.
    Arthritis Rheum; 2005 Jul 15; 52(7):2103-8. PubMed ID: 15986366
    [Abstract] [Full Text] [Related]

  • 18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 19. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
    Pham T, Landewé R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D.
    Ann Rheum Dis; 2006 Dec 15; 65(12):1620-5. PubMed ID: 16464984
    [Abstract] [Full Text] [Related]

  • 20. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
    van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS.
    Ann Rheum Dis; 2013 Jul 15; 72(7):1221-4. PubMed ID: 23264358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.